key: cord-1039776-np90e50b authors: Sayad, Babak; Karimi, Mehran; Rahimi, Zohreh title: Sickle cell disease and COVID‐19: Susceptibility and severity date: 2021-06-01 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29075 sha: 973fd305132465261ccc74b18d004515b678bbd1 doc_id: 1039776 cord_uid: np90e50b We surveyed published papers and an international sickle cell disease (SCD) registry to detect susceptibility and clinical course of coronavirus disease 2019 (COVID‐19) in SCD patients. COVID‐19 presentation was mild in children and moderate in many SCD adults. Regarding increased comorbidities with age, it seems severe COVID‐19 to be more common in older SCD patients. Although the overall outcome of COVID‐19 was favorable in SCD children, a high rate of pediatric intensive care unit admission should be considered in managing these patients. To explain COVID‐19 outcome in SCD patients, the possible benefits of hydroxyurea therapy could be considered. The obtained results should be interpreted, considering low cases from sub‐Saharan people, younger age of SCD patients compared to general population, a bias toward registry of the more severe form of disease, the effect of pre‐existing comorbidities with multisystem organ damage, and the role of health socio‐economic determinants. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID- 19) , results in a cytokine storm with damage to organs, mainly lungs in severely affected patients. 1 Hemoglobin S (HbS), an abnormal structural hemoglobin variant, results from valine substitution for glutamic acid at the sixth position of the beta globin chain of hemoglobin. This alteration results in the polymerization of hemoglobin in low oxygen saturation, the deformity of red blood cells, and microvascular occlusion. 2 About 5% of the population in the world is the carrier of hemoglobinopathies, mainly sickle cell disease (SCD), with a carrier prevalence of 10-45% of sub-Saharan Africa population for sickle cell gene. 3 COVID-19 pandemic emerged as a concern about greater susceptibility of SCD patients to COVID- 19 fied the SCD as one of the conditions to be considered at increased risk of severe illness from COVID-19 infection. 4 Since SCD patients (1) have underlying pathophysiology of chronic inflammation with increased risk of thrombosis, 5 (2) are immunocompromised due to auto-infarction of their spleen or surgical splenectomy and especially prone to infectious diseases and acute chest syndrome (ACS), 6 and (3) have the comorbidities and secondary organ dysfunction, 7, 8 there is concern about susceptibility and COVID-19 severity in these patients. The present review aimed to summarize and analyze the susceptibility of SCD patients to COVID-19 and its severity. reaction (RT-PCR). One study from Oman due to incomplete information and possible overlap with another study from this country reported in this review was omitted. Data presented in the text, the tables of scientific documents, and the website of international SCD registry, 9 and also US registry 10 patients in the registry, 9 it was not clear that each individual had one comorbidity or there might be more than one comorbidity in a patient. Pediatric ICU (PICU) admission was nine out of 40 (22.5%) in published papers, and in the report of international SCD registry 9 was 23 out of 365 (6.3%) ( Table 1) . Regarding available data, 19 out of 38 pediatric patients were on HU therapy (50%), and in the international SCD registry report, 9 there were 203 out of 365 (55.6%) ( Table 1) . The mean HbF level was available in three studies 11,15,18 as 17.7%, 12.3%, and 11.3%, respectively. Considering SECURE-SCD Registry of the Medical College of Wisconsin, among 134 adult SCD patients, ICU admission rate was 11%, and mortality rate was 7%. Mortality rate was higher among milder SCD genotypes compared to severe genotypes. However, the presence of a bias toward a more severe form of disease in this registry and pre-existing comorbidities with multisystem organ damage in the exacerbation of COVID-19 and fatality rate in SCD patients should be considered. 10 Around 40% of deaths were among patients who had milder SCD genotypes (HbSC or HbSβ + -thalassemia). 10 In one large study from five referral SCD centers in the United States, 66 SCD patients with COVID-19, including 57 adults, were detected from 3500 adult and pediatric patients with SCD. The median age was 34 years (the age range was 8 months to 69 years). The mortality rate was 10.6%, which was higher than the general population (3.3%). 19 HU was a protective factor, and all dead patients were not taking HU. The mortality rate was higher than the US-based registry (7%) and a European study, which seems to be due to this study's older age range. The study results showed older age with pre-existing chronic organ damage of kidneys, heart, lung, and brain were at high risk of morbidity regardless of hemoglobin genotype. SCD patients with pulmonary hypertension seem to be at the highest risk of mortality with COVID-19. Twelve out of 66 patients (18.2%) had a history of splenectomy. Moreover, patients with increased levels of lactate dehydrogenase (LDH) and D-dimer were at higher risk of death. 19 In a report of 24 SCD cases from United States, a mild clinical course of COVID-19, low rate of intubation, ICU admission, and death was observed. Ninety-two percent of patients were African American, and 63% had at least one comorbidity. Only one patient with sickle cell trait who was on chronic immunosuppressive therapy and required ICU admission died. None of the SCD patients received HU therapy. 20 A mild clinical course of COVID-19 disease existed in an HbS/β 0 -thalassemia patient on HU therapy 21 and four SCD cases from the United States. 22 In a multicenter study from France, consisting Except references 9, 10, 14, the percentage of SCD genotype was considered in all patients and presented in Table 2 . of 71 inpatient SCD with COVID-19 (15-74 years), mostly adults with SS/Sβ 0 , SC, Sβ + -thalassemia genotype 14 The most common symptoms in the symptomatic SCD children with In other studies, the most common symptoms among children were fever and ACS, 7 and in adults were cough, fever, myalgia, shortness of breath, chills, 20 fever, myalgia, back pain, and cough. 24 SCD patients are immunocompromised with multiple comorbidities and a hypercoagulable state. SCD patients with COVID-19 show a wide range of severity, which might be associated to a higher risk of morbidity and mortality. It seems severe COVID-19 to be common in older SCD patients, because the comorbidities are increased once SCD patients become older. 19 Note: Comorbidity included ACS, asthma, avascular necrosis, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, obesity, hypertension, painful crisis, pulmonary embolism, pulmonary hypertension, splenectomy, chronic kidney disease, malignancy, seizure, sickle cell nephropathy, stroke, venous thromboembolism. Abbreviations: ACS, acute chest syndrome; COVID-19, coronavirus disease 2019; HU, hydroxyurea; ICU, intensive care unit; NA, not available; SCD, sickle cell disease; SS, sickle cell homozygous a Some patients had more than one comorbidity. b Study included 57 adults and nine children, and except for mortality other parameters were not separately described in patients, and the numbers were based on all 66 patients. c In references 9, 10, 14, and 19, the percentage of SCD genotype was considered in all patients. presence of comorbidities in 65.8% of pediatric SCD patients should be considered for a higher mortality rate. The death rate increased in the presence of comorbidities as a death rate of 4% was reported in children infected with SARS-CoV-2; 83% of them had pre-existing comorbidity. 36 Furthermore, in a report of 46 children and adolescents positive for COVID-19, 28.3% were admitted to PICU and the death rate was 2.2%, and the most prevalent comorbidities were obesity and asthma. 37 The overall outcome of COVID-19 was favorable in SCD children; the high rate of PICU admission (22.5%) and need for PICU support should be considered in managing these patients. ICU admission was 12%, and the death rate was 7.6% in SCD adults infected with SARS-CoV-2. As per the World Health Organization (WHO) report updated on April 5, 2021, the overall death rate from Since only four SCD patients with splenectomy and good outcomes were reported, 7,11,15,30 the possible benefit of splenectomy against the produced cytokine storm in COVID-19 patients needs to be elucidated. (3) Although none of the reports discussed the ferritin levels and iron chelation therapy in SCD patients with COVID-19, high ferritin levels represent a negative prognostic factor in patients with COVID-19 and iron chelation with deferiprone or deferoxamine, which was proposed for COVID-19 therapy, reduced viral replication and related proinflammatory pathways. 52 Hence, iron chelation in SCD patients who need transfusion might also be beneficial against COVID-19, and it should be further confirmed. SCD patients are immunocompromised with multiple comorbidities and a hypercoagulation state. Older patients with pre-existing multiple organ damage are at higher risk of morbidity and mortality from COVID-19, and hemoglobin genotype, or gender seems to be not asso- COVID-19 and psoriasis: biologic treatment and challenges Splenic complications of sickle cell anemia and the role of splenectomy Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries Thromboinflammatory mechanisms in sickle cell disease -challenging the hemostatic balance Sickle cell disease Varying presentations and favourable outcomes of COVID-19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy Updates and Data Coronavirus disease among persons with sickle cell disease Acute chest syndrome in the setting of SARS-COV-2 infections-a case series at an urban medical center in the Bronx SARS-CoV-2 infection in pediatric patient with hemoglobin SC disease. Pediatr Blood Cancer A pediatric patient with sickle cell disease presenting with severe anemia and splenic sequestration in the setting of COVID-19 Prognosis of patients with sickle cell disease and COVID-19: a French experience Patients with sickle cell disease and suspected COVID-19 in a pediatric ICU Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection Impact of COVID-19 infection on 24 patients with sickle cell disease. One center urban experience COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient COVID-19 infection in patients with sickle cell disease Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab Low morbidity and mortality with COVID-19 in sickle cell disease: a single center experience COVID-19 infection and sickle cell disease: a UK centre experience COVID-19 in patients with sickle cell disease-a case series from a UK tertiary hospital Vasoocclusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) Sickle cell disease and COVID-19: atypical presentations and favorable outcomes. EJHaem Acute lung failure due to COVID-19 in a patient with sickle cell anemia A Saudi family with sickle cell disease presented with acute crises and COVID-19 infection Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-A study COVID-19 and sickle cell disease in Bahrain Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection The role of red blood cell exchange in sickle cell disease in patient with COVID-19 infection and pulmonary infiltrates COVID-19 in 7780 pediatric patients: a systematic review Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units Clinical characteristics and outcomes of hospitalized and critically III children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York city Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic Sickle cell trait and the potential risk of severe coronavirus disease 2019-a mini-review COVID-19 outcomes in individuals with sickle cell disease and sickle cell trait compared to Blacks without sickle cell disease or trait Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa COVID-19 in Africa: no room for complacency Effects of hydroxyurea treatment for patients with hemoglobin SC disease Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea immunohistochemical, and biomechanical effects of splenectomy on Achilles tendon healing in rats COVID-19, hemoglobin, iron and hypoxia beyond inflammation. A narrative review The authors declare that there is no conflict of interest. Mehran Karimi https://orcid.org/0000-0001-8555-1001Zohreh Rahimi https://orcid.org/0000-0001-7589-3307